The specialty’s leading advocate, the Advocacy Council, is committed to bringing you news and insights on billing, coding and policy reform that directly affect your practice. Advocacy Insider, a recurring column in College Insider, keeps you in the loop.
Contact us at AdvocacyCouncil@acaai.org or 847-427-1200.
- Show all
- A/I Action
- Advocacy Alert
- Advocacy Resources
- AllergyWatch
- Annals
- Annual Meeting
- CA2PER Program
- College Advantage
- Committees
- COVID-19
- Education
- Event
- Foundation
- From College Leadership
- Gold Headed Cane
- History
- House of Delegates
- Member benefit
- New Allergists
- News
- Opinion
- Patient Brochures
- Resources
- Survey
- Time For An Allergist
- Uncategorized
- Webinar
2025 Medicare Physician Fee Schedule Final Rule
This article summarizes key proposals concerning the Medicare Physician Fee Schedule that impact allergy practices.
How do MACs impact patients
To process Medicare claims, MACs are awarded geographic jurisdictions in which they serve as primary contacts
2024 MIPS and APM changes
This article provides a summary of key, final changes to the QPP governing the traditional Merit-based Incentive Payment System program.
EFT fees burden physician offices
For years, physicians have faced reduced payments from commercial health plans using virtual credit cards and third-party electronic payment vendors for standa…
2024 MIPS Proposed Changes
This article provides a summary of key proposals and changes to the traditional MIPS program that will impact allergists.
2023 budget bill will result in 2% Medicare pay cut for allergists
Allergists were previously facing Medicare payment cuts of up to 8.5%, but under the budget bill, allergists will incur a 2% Medicare payment cut in 2023.
2023 Medicare reimbursement cuts
Beginning Jan. 1, 2023, allergists are facing up to a 10% reduction in Medicare reimbursement unless Congress takes legislative action to avert these cuts.
2023 Proposed MIPS Changes
For the 2023 performance year, CMS is required to weigh the cost and quality performance categories equally.
Tezspire administration remains an in-office procedure
Medicare Administrative Contractors publicly announced removal of Tezspire from their Self-Administration Drug (SAD) exclusion lists.
Drug prices lowered for Medicare beneficiaries and ACA subsidies extended
After more than a year of trying to pass the Build Back Better Act, Congress passed a slimmer version, the Inflation Reduction Act.
